These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 6696467)

  • 21. Daily practice assessment of liver injury in patients with psoriasis on methotrexate.
    Driessen RJ; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2010 Jan; 162(1):211-3. PubMed ID: 19903179
    [No Abstract]   [Full Text] [Related]  

  • 22. Liver injury associated with methotrexate therapy for psoriasis.
    Podurgiel BJ; McGill DB; Ludwig J; Taylor WF; Muller SA
    Mayo Clin Proc; 1973 Nov; 48(11):787-92. PubMed ID: 4758150
    [No Abstract]   [Full Text] [Related]  

  • 23. Risk: benefit ratio in the treatment of psoriasis with systemic retinoids.
    Halioua B; Saurat JH
    Br J Dermatol; 1990 Jun; 122 Suppl 36():135-50. PubMed ID: 2142437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatotoxicity of long-term methotrexate therapy for psoriasis.
    Tobias H; Auerbach R
    Arch Intern Med; 1973 Sep; 132(3):391-6. PubMed ID: 4783020
    [No Abstract]   [Full Text] [Related]  

  • 25. [Laboratory and oligobiopsy examination of the liver in patients with psoriasis treated with methotrexate (preliminary report)].
    Ruszczak Z; Prószyńska-Kuczyńska W; Babiński S; Biernat S; Kulig A
    Przegl Dermatol; 1974; 61(6):803-7. PubMed ID: 4431967
    [No Abstract]   [Full Text] [Related]  

  • 26. A case of hepatitis related to etretinate therapy and hepatitis B vaccine.
    Green C; Lakshmipathi T
    Dermatologica; 1991; 182(2):119-20. PubMed ID: 1828773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy for psoriasis with methotrexate and etretinate.
    Tuyp E; MacKie RM
    J Am Acad Dermatol; 1986 Jan; 14(1):70-3. PubMed ID: 3950115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A study of potential hepatotoxicity of etretinate used in the treatment of psoriasis.
    Glazer SD; Roenigk HH; Yokoo H; Sparberg M
    J Am Acad Dermatol; 1982 Apr; 6(4 Pt 2 Suppl):683-7. PubMed ID: 7068976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse hepatic reactions associated with etretinate in patients with psoriasis--analysis of 22 cases.
    Thirumoorthy T; Shupack JL
    Ann Acad Med Singap; 1988 Oct; 17(4):477-81. PubMed ID: 3066276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of risk factors in psoriatic patients with methotrexate-induced increases in transaminase levels.
    Heydendael VM; Spuls PI; Bossuyt PM; Bos JD; de Rie MA
    Arch Dermatol; 2004 Oct; 140(10):1289-90. PubMed ID: 15492205
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of generalized pustular psoriasis with etretinate (Ro 10-9359) and methotrexate.
    Rosenbaum MM; Roenigk HH
    J Am Acad Dermatol; 1984 Feb; 10(2 Pt 2):357-61. PubMed ID: 6707259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of methotrexate in psoriasis.
    Roenigk HH; Maibach HI; Weinstein GD
    Arch Dermatol; 1972 Mar; 105(3):363-5. PubMed ID: 5012144
    [No Abstract]   [Full Text] [Related]  

  • 33. [Limitations and risks of therapy of psoriasis with amethopterin and hydroxyurea].
    Ottolenghi F; Andreassi L
    G Ital Dermatol Minerva Dermatol; 1971 Sep; 46(9):385-96. PubMed ID: 4255617
    [No Abstract]   [Full Text] [Related]  

  • 34. Methotrexate induced liver disease in psoriasis.
    Millward-Sadler GH; Ryan TJ
    Br J Dermatol; 1974 Jun; 90(6):661-7. PubMed ID: 4853200
    [No Abstract]   [Full Text] [Related]  

  • 35. Liver biopsies in patients on methotrexate for the treatment of psoriasis.
    Callen JP; Hanno R
    Int J Dermatol; 1980 May; 19(4):215. PubMed ID: 7399793
    [No Abstract]   [Full Text] [Related]  

  • 36. Methotrexate therapy of psoriasis. Effect and side effects with particular reference to hepatic changes. A survey.
    Nyfors A
    Dan Med Bull; 1980 Apr; 27(2):74-96. PubMed ID: 7000451
    [No Abstract]   [Full Text] [Related]  

  • 37. Methotrexate pharmacokinetics in psoriatic patients developing hepatic fibrosis.
    Jones SK; Aherne GW; Campbell MJ; White JE
    Arch Dermatol; 1986 Jun; 122(6):666-9. PubMed ID: 3717976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hazards of prolonged low-dose methotrexate therapy.
    Bender AS
    Va Med Mon (1918); 1970 Apr; 97(4):218-9. PubMed ID: 5317468
    [No Abstract]   [Full Text] [Related]  

  • 39. [Oral methotrexate therapy: pro and con].
    Zachariae H
    Hautarzt; 1985 Jan; 36(1):10-2. PubMed ID: 3972575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive value of HLA antigen for methotrexate-induced liver damage in patients with psoriasis.
    Pestana A; Halprin KM; Taylor JR; Schiff ER; Esquenazi V; Comerford M; Gomez C
    J Am Acad Dermatol; 1985 Jan; 12(1 Pt 1):26-9. PubMed ID: 3980800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.